BioSpace: Biotech, Pharmaceutical and Clinical Research News
PBMs. Deep Dive: PBM Reform. In the battle over drug prices, one sector of the healthcare industry has risen above all the players as the boogeyman: pharmacy benefit managers. In this special edition of BioPharm Executive, BioSpace takes a deep dive into the lens now focused on PBMs’ business practices. September 18, 2024.
Roche Inks Potential $1.8B Deal With Flare to Target ... - BioSpace
2 days ago · Roche on Tuesday entered into a back-heavy oncology deal with Flare Therapeutics, paying $70 million upfront to discover and advance new small molecule drug candidates against previously undruggable transcription factors to enhance or suppress the expression of particular genes. Under the deal, Massachusetts-based Flare will be entitled to discovery, development …
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more
2 days ago · Revenue: $26 million Cash position: $676.7 million Runway: Into 2027 Arcellx is heading into the fourth quarter on the cusp of a make-or-break milestone. The biotech and partner Gilead reported results earlier this week for CAR T therapy anitocabtagene autoleucel (anito-cel) that showed strong response rates and improved survival outcomes in patients with relapsed …
All News - BioSpace
3 days ago · BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special. November 12, 2024. ·. 6 min read.
Approvals - BioSpace
Oct 30, 2024 · Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population. Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease. October 23, 2024.
Latest News & Press Releases - BioSpace
6 days ago · Press Releases. Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers.
FDA News: Approvals, Adcomms, Complete Response Letters and …
Adcomms. Complete response letters. Guidances. FDA Tracker. Intercept’s Ocaliva Continues Losing Streak as FDA Denies Full Approval. In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA’s decisions in 2024. November 12, 2024.
Biopharma Business News - BioSpace
2 days ago · Driven by copycat versions of Bristol Myers Squibb’s Revlimid and Novo Nordisk’s Victoza, Teva’s generics business was again a top-performer in the third quarter, with U.S. sales growing 30% and bringing in $1.1 billion in sales. BioSpace …
Reports - BioSpace
Jul 24, 2024 · 2024 Q2 Job Market Report: More People Competing for Fewer Job Openings. For the second quarter of 2024, there were 25% fewer jobs posted live on BioSpace compared to the same quarter of 2023. The year-over-year job response rate …
Clinical research - BioSpace
Nov 5, 2024 · Viking Touts Promising Phase I Weight Loss Data for Obesity Pill Candidate. Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy VK2735 exceeded expectations, with “class-leading” weight loss. Patients on 100-miligram doses of the pill lost 8.2% of their body weight after ...